Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
On June 15, 2026, Obexelimab — Zenas BioPharma, Inc. (IgG4 Related Disease) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.5% in the window around the event. It had already run +8.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
CatalystAlert called this one up (+6.3% expected); the stock actually moved -5.5%. Model confidence at the time: 60%.
See the full scored track record